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Purpose: It has recently been shown that chronic noninvasive ventilation (NIV) improves a 
number of outcomes including survival, in patients with stable hypercapnic COPD. However, 
the mechanisms responsible for these improved outcomes are still unknown. The aim of the 
present study was to identify parameters associated with: 1) an improved arterial partial pressure 
of carbon dioxide (PaCO
2
) and 2) survival, in a cohort of hypercapnic COPD patients treated 
with chronic NIV.
Patients and methods: Data from 240 COPD patients treated with chronic NIV were ana-
lyzed. Predictors for the change in PaCO
2
 and survival were investigated using multivariate 
linear and Cox regression models, respectively.
Results: A higher level of bicarbonate before NIV initiation, the use of higher inspiratory venti-
lator pressures, the presence of anxiety symptoms, and NIV initiated following an exacerbation 
compared to NIV initiated in stable disease were associated with a larger reduction in PaCO
2
. A 
higher body mass index, a higher FEV
1
, a lower bicarbonate before NIV initiation, and younger 
age and NIV initiation in stable condition were independently associated with better survival. 
The change in PaCO
2
 was not associated with survival, neither in a subgroup of patients with 
a PaCO
2
 .7.0 kPa before the initiation of NIV.
Conclusion: Patients with anxiety symptoms and a high bicarbonate level at NIV initiation are 
potentially good responders in terms of an improvement in hypercapnia. Also, higher inspiratory 
ventilator pressures are associated with a larger reduction in PaCO
2
. However, the improvement 
in hypercapnia does not seem to be associated with an improved survival and emphasizes the 
need to look beyond PaCO
2
 when considering NIV initiation.
Keywords: carbon dioxide, home mechanical ventilation, exacerbation, bicarbonate, chronic 
obstructive pulmonary disease, respiratory insufficiency
Introduction
COPD is a leading cause of morbidity and mortality worldwide and constitutes a major 
healthcare burden.1,2 In the advanced stages of the disease, patients frequently develop 
chronic hypercapnic respiratory failure (CHRF). Noninvasive ventilation (NIV) is the 
standard treatment for patients with CHRF due to restrictive lung disease. In patients 
with CHRF due to COPD, chronic NIV has led to clinically relevant improvements in 
dyspnea, gas exchange, lung function, and health-related quality of life (HRQL), when 
sufficient inspiratory pressures and backup respiratory rates were applied.3–5 This so 
called high-intensity NIV is aimed at a substantial reduction in arterial partial pressure of 
carbon dioxide (PaCO
2
).5 A randomized controlled trial (RCT) by Köhnlein et al, using 
this NIV strategy, was the first to demonstrate a survival benefit in stable hypercapnic 
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COPD patients after 1 year of NIV.6 As a result, chronic NIV 
is nowadays a standard treatment for COPD patients with 
CHRF and a major indication for home mechanical ventila-
tion (HMV) in Europe.7
Nevertheless, it remains unknown how chronic NIV 
actually leads to these improved outcomes. While it has been 
hypothesized that a substantial reduction in hypercapnia is 
responsible for the merits of NIV and improved survival of 
patients on chronic NIV, a survival benefit has also been 
shown without a change in daytime hypercapnia and not all 
studies showing a reduction in hypercapnia could demon-
strate improvements in survival.5,8,9 Therefore, chronic NIV 
might affect outcomes through several different mechanisms. 
With a growing prevalence of COPD, it is expected that the 
number of patients requiring NIV will increase. As it is clear 
that not all patients respond favorably to NIV, it needs to 
be determined which subgroup benefits most from chronic 
NIV, before this costly therapy can be implemented on a 
broader scale.
The aim of the present study was to identify parameters 
associated with a favorable response to chronic NIV in terms 
of: 1) change in PaCO
2
 after 1 year of NIV and 2) survival, 
in a cohort of hypercapnic COPD patients treated with 
chronic NIV.
Patients and methods
This is a prospective observational cohort study of a popula-
tion of COPD patients treated with chronic NIV by the HMV 
center of the University Medical Center Groningen from 2005 
to 2015. Data were collected in two RCTs; the RECOVER 
and the RESCUE trial. The RECOVER trial (ClinicalTrial 
NCT00135538) aimed to investigate the addition of chronic 
NIV to pulmonary rehabilitation in patients with stable 
CHRF (daytime PaCO
2
 .6.0 kPa). In the RESCUE trial 
(trial registration number NTR1100), patients with acute 
respiratory failure (ARF) continued NIV at home, if they 
had persistent hypercapnia after treatment with ventilator 
support. Both trials excluded patients with severe cardiac or 
neuromuscular disease and patients with an apnea–hypopnea 
index .15 per hour. Medical Ethical Committee approval 
(Medisch Ethische Toetsingscommissie of the University 
Medical Center Groningen) and written informed consent 
were obtained for the two trials.
As part of regular clinical practice in our center, COPD 
patients are initiated on chronic NIV in addition to pulmonary 
rehabilitation and are followed prospectively. Patients have 
an indication for chronic NIV once they have COPD GOLD 
stage III or IV combined with CHRF (PaCO
2
 .6.0 kPa) in a 
stable clinical condition. Data from these patients were also 
analyzed for this study.
Measurements
The following parameters were recorded before NIV initia-
tion (baseline) and during follow-up after 3 and 12 months: 
demographics, comorbidities, body mass index (BMI), blood 
gasses, lung function, medication, and ventilator settings. 
Lung function was measured on patients’ own bronchodila-
tors, and arterial blood gasses were drawn with the regular 
amount of oxygen applied. In patients initiated outside the 
trials, 3- and 12-month follow-up outcomes were collected 
between 2–3 months and 9–14 months, respectively, after NIV 
initiation. In both trials, the severe respiratory insufficiency 
(SRI) questionnaire was administered to assess HRQL. The 
SRI is a validated and highly specific tool for assessing 
HRQL in patients with CHRF.10 The validated Hospital 
Anxiety and Depression Scale (HADS) was administered 
in both studies for screening of symptoms of anxiety and 
depression (HADS score $8 point per domain).11 The HADS 
was not administered in patients initiated on NIV in regular 
care. These patients were assessed by a qualified psycholo-
gist, screening for symptoms of anxiety and depression (as 
part of our pulmonary rehabilitation program).
In both trials, polygraphies were conducted in patients 
with a BMI .30 kg/m2, who snored or had complaints of 
disrupted sleep, excessive daytime sleepiness, or morn-
ing headache. In patients initiated as part of regular care, 
polygraphies were conducted only in patients with a clinical 
suspicion. In addition, medical records were investigated for 
the diagnosis obstructive sleep apnea (OSA) or treatment 
with continuous positive airway pressure. Furthermore, the 
diagnosis of diabetes mellitus, hypertension, coronary artery 
disease, or congestive heart failure were identified in the 
medical records of all patients.
noninvasive ventilation
All patients were initiated on NIV by the same registered nurse 
according to a standardized high-intensity protocol. NIV was 
supplied through a pressure cycled ventilator, applying both 
an inspiratory and expiratory positive airway pressure, with 
a backup respiratory rate (BiPAP Synchrony® and A30®, 
Respironics, Murrysville, PA, USA). The effectiveness of 





 saturation (TOSCA® 500, Linde Medical 
Sensors AG, Basel, Switzerland). Supplementary oxygen was 
applied through the ventilator in regular amount. Monitoring 
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Improvement in hypercapnia does not predict survival in COPD patients
statistical analyses
Results are presented as mean±SD or medians and inter-
quartile range (IQR). Normality of the distribution was 
tested by visual inspection of normal probability plots and 
histograms and checked with the Kolmogorov–Smirnov test. 
The independent samples t-test and chi-squared test, or non-
parametric equivalent, were used to compare baseline charac-
teristics of patients initiated in stable condition and patients 
initiated after an exacerbation. Variables with more than 
40% of missing values were excluded from the analysis.
To assess prognostic value of baseline variables on the 
change in PaCO
2
, univariate regression analyses were per-
formed with percentage of change in PaCO
2
 after 12 months 
as the dependent variable and baseline measurements as inde-
pendent variables, ie, predictors. As the dependent variable is 
a change score, baseline PaCO
2
 was only excluded from this 
analysis. All variables that were associated with the change in 
PaCO
2
 in the univariate analysis (ie, P-value ,0.1), and age, 
gender and diuretic use were entered in the final multivariate 
linear regression model.
The prognostic value of each baseline variable on mor-
tality was assessed in the intention-to-treat population by 
a univariate Cox regression from initiation of NIV until 
1 January 2016. The proportional hazards assumption was 
assessed by visual inspection of log–log plots. All variables 
that were associated with survival in a univariate analysis 
(P-value ,0.1) and age, gender, and diuretic use were entered 
in the final multivariate Cox regression. Due to the strong 
association between baseline PaCO
2
 and bicarbonate levels, 
the variable with the lowest P-value was included.
All statistical analyses were performed using IBM SPSS 




As depicted in Figure 1, 250 patients started with chronic 
NIV. Ten patients were excluded from the analyses because 
insufficient data were available. Table 1 shows the baseline 
characteristics for the whole group as well as separately for 
the COPD patients initiated in stable condition and for the 
COPD patients initiated after an episode of ARF. Anxiety 
and depression symptoms were reported in 39% and 42% 
of the patients, respectively. Diabetes was present in 19% of 
the patients, hypertension in 34%, coronary artery disease in 
14%, and congestive heart failure in 13% of the patients.
Figure 1 Flowchart of the study.
Note: aDiscontinued nIV due to lung transplantation, lung volume reduction therapy, or recovery of respiratory failure.
Abbreviations: nIV, noninvasive ventilation; arF, acute respiratory failure.
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During follow-up, 111 patients died at a median time of 
14 (IQR 8–31) months after NIV initiation. All-cause mor-
tality after 1 year was 23%. Fifty-seven patients were still 
treated at the time of this evaluation (median duration on 
NIV: 44 [IQR 23–70] months) and 49 patients dropped out 
because of nontolerance/noncompliance (after a median dura-
tion of NIV of 2 [IQR 1–7] months). These patients did not 
differ from compliant patients in baseline characteristics and 
comorbidities. In 11 patients, NIV was no longer needed due 
to lung transplantation (n=8), lung volume reduction therapy 
(n=1), or recovery of respiratory failure (n=2). Finally, long-
term follow-up data of 12 patients could not be retrieved.
noninvasive ventilation
After 3 months, mean inspiratory positive airway pressure 
was 21.9±3.9 (IQR 20–24), expiratory positive airway 
pressure was 5.6±1.6 (IQR 4–6) cm H
2
O, and backup 
respiratory rate was 15.9±2.8 breaths per minute. Compli-
ance to the ventilator after 3 months was 6.6±2.0 hours 
per night and 80% of the patients used NIV for more than 
5 hours per night. Compliance among patients who died was 
not different from patients who were alive at the time of the 
analysis (P=0.302), and compliance did not differ between 
patients feeling anxious (P=0.520) or depressed (P=0.220) 
and patients without these symptoms.
Predictors of change in PaCO2
According to the univariate regression, age, timing of 
NIV initiation, the SRI total score, and baseline bicarbon-
ate levels were associated with the change in PaCO
2
 after 
12 months (Table S1). In the multivariate regression model, 
a higher baseline bicarbonate level and inspiratory pres-
sure, initiation after an exacerbation instead of initiation 
Table 1 Baseline characteristics of the total group of COPD patients (n=240) and separately of patients initiated in stable condition 
(n=117) and of patients initiated after an episode of arF (n=123)
Total group (n=240) Stable COPD (n=117) After ARFb (n=123) P-value
age (years) 62.5 (8.9) 61.8 (9.1) 63.2 (8.6) 0.235
gender (M), n (%) 104 (43) 50 (43) 54 (44) 0.855
smoker, n (%) 55 (23) 24 (21) 31 (25) 0.369
Pack yearsa 39 (23–50) 40 (27–45) 38 (21–56) 0.850
living alone, n (%) 50 (23) 19 (16) 31 (25) 0.087
exacerbations (n)a,c 2 (0–3) 1 (0–2) 2 (1–4) 0.001
BMI (kg/m2) 25.6 (5.9) 26.5 (6.0) 24.8 (5.6) 0.033
PaO2 (kPa) 7.9 (1.4) 8.1 (1.4) 7.8 (1.5) 0.269
PaCO2 (kPa)
a 7.4 (6.8–8.4) 7.2 (6.6–7.9) 7.8 (7.1–9.0) ,0.001
hCO3
- (mmol/l) 33.0 (1.5) 31.7 (3.9) 34.0 (4.7) ,0.001
FVC (l) 2.1 (0.7) 2.2 (0.6) 2.1 (0.7) 0.188
FeV1 (l)
a 0.63 (0.49–0.81) 0.64 (0.49–0.79) 0.62 (0.49–0.83) 0.741
FeV1/FVC (%) 33 (9) 31 (8) 34 (10) 0.051
TlC (l) 7.3 (1.5) 7.3 (1.5) 7.2 (1.6) 0.918
rV (l) 4.8 (1.3) 4.9 (1.3) 4.7 (1.6) 0.696
rV/TlC (%)a 69 (60–72) 69 (62–72) 66 (54–73) 0.475
srI, total score 49.9 (15.0) 54.6 (14.3) 47.9 (14.9) 0.020
haDs, total score 15.3 (8.7) 13.9 (7.1) 16.0 (9.2) 0.214
lTOT, n (%) 170 (72) 80 (68) 90 (73) 0.352
Medication, n (%)
Inhaled corticosteroid 210 (88) 107 (92) 103 (84) 0.096
Oral corticosteroid 142 (59) 59 (50) 83 (68) 0.006
Beta agonist 233 (98) 113 (97) 120 (98) 0.379
anticholinergics 227 (95) 111 (95) 116 (94) 0.941
Theophylline 74 (31) 35 (30) 39 (32) 0.732
Diuretics 105 (44) 55 (47) 50 (41) 0.321
Notes: last column shows P-value for comparison between patients initiated in stable condition and patients initiated after acute respiratory failure ceased but remaining 
hypercapnic. Data are presented as mean (sD) or amedian (IQr); bnIV initiated after acute respiratory failure resolved and patients remained hypercapnic; cnumber of 
exacerbations in 12 months prior to NIV initiation. The values in bold are considered statistically significant (P,0.05). haDs, a higher score indicates more symptoms of 
anxiety and depression.
Abbreviations: arF, acute respiratory failure; haDs, hospital anxiety and Depression scale; hCO3
-, arterial bicarbonate; lTOT, long-term oxygen therapy; nIV, 
noninvasive ventilation; PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; RV, residual volume; SRI, severe respiratory insufficiency questionnaire; 
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Improvement in hypercapnia does not predict survival in COPD patients
in stable disease, and the presence of anxiety symptoms 
were related to a larger decrease in PaCO
2
 after 12 months 
(Table 2).
Predictors of survival





bicarbonate levels, OSA, and timing of NIV initiation were 
significant determinants of survival (Table S2). Of note, the 
absolute and percentage of change in PaCO
2
 after 12 months 
were not associated with survival. Therefore, we conducted 
a subgroup analysis on patients with severe hypercapnia 
(baseline PaCO
2
 .7.0 kPa, (median 8.0 [7.3–9.0] kPa, 
n=163)). Also in this subgroup, the change in PaCO
2
 after 
12 months was not associated with survival.
The multivariate Cox regression revealed that a higher 
age and baseline bicarbonate levels, and initiation after an 
exacerbation remained independently associated with an 
impaired prognosis, while patients with a higher BMI and 
FEV
1
 seemed to have a better prognosis (Table 3). Figure 2 
illustrates the prognostic value of the timing of NIV initiation 
(Figure 2A) and of the percentage of change in PaCO
2
 after 
12 months (Figure 2B) on survival.
Discussion
The present study suggests that COPD patients with anxiety 
symptoms and high bicarbonate levels at initiation of NIV 
benefit most of chronic NIV in terms of improvement in 
PaCO
2
. Also, we confirmed that with higher inspiratory 
ventilator pressures a more pronounced improvement in 
gas exchange can be achieved. However, improvements in 
PaCO
2
 do not seem to influence survival. This suggests that 
NIV might improve survival in a subgroup of patients irre-
spective of the ability to improve PaCO
2
 and emphasizes the 
need to look beyond PaCO
2
 when treating COPD patients 
with chronic NIV.
Chronic NIV as a treatment for CHRF in COPD patients 
has long been controversial. In 2014, Köhnlein et al published 
the results of an important landmark study, as it showed an 
impressive survival benefit when chronic NIV was applied 
in COPD patients with severe CHRF.6 With this study, 
evidence for the use of NIV received an enormous boost. 
However, it is still unclear exactly how and why chronic 
NIV improves survival.
The focus of high-intensity NIV is currently on achieving 
a maximal reduction in PaCO
2
.5 Previous studies have shown 
conflicting results regarding the influence of chronic hyper-
capnia on prognosis.12,13 If hypercapnia is associated with 
bad prognosis, it would be more logical that by decreasing 
Table 2 Prognostic value of baseline parameters for the 
percentage of change in PaCO2 after 12 months for the total 
group of COPD patients according to the multivariate regression 
model
∆PaCO2a
B 95% CI of B P-value
Constant 38.84 8.59 to 69.10 0.013
hCO3
- (mmol/l) -1.29 -1.89 to -0.70 ,0.001
nIV started after arF -5.54 -10.73 to -0.36 0.036
anxiety -7.48 -13.64 to -1.32 0.018
IPaP (cmh2O)
b -0.78 -1.49 to -0.07 0.032
age (years) 0.26 -0.04 to 0.57 0.088
gender (F) -0.16 -5.11 to 4.79 0.949
FeV1 (% predicted) -0.19 -0.46 to 0.86 0.177
Depression -0.71 -5.14 to 6.56 0.810
Diuretics 3.46 -1.44 to 8.37 0.164
Congestive heart failure -1.32 -7.95 to 5.31 0.693
R2 0.435
n 84
Notes: aPercentage of change in PaCO2 after 12 months, a negative value indicates 
a decrease in PaCO2; 
bIPaP after 12 months. The values in bold are considered 
statistically significant (P,0.05).
Abbreviations: arF, acute respiratory failure; hCO3
-, arterial bicarbonate; IPaP, 
inspiratory positive airway pressure; nIV, noninvasive ventilation; PaCO2, arterial 
carbon dioxide pressure.
Table 3 Prognostic value for baseline parameters on survival according to the multivariate Cox regression analysis
Parameter estimate Standard error HR 95% CI P-value
age (years) 0.05 0.02 1.05 1.01 to 1.08 0.008
BMI (kg/m2) -0.07 0.03 0.94 0.89 to 0.99 0.011
nIV started after arF 0.59 0.26 1.81 1.06 to 3.08 0.029
hCO3
- 0.06 0.03 1.06 1.00 to 1.12 0.049
FeV1 (% predicted) -0.04 0.02 0.96 0.93 to 0.99 0.007
Diuretics 0.46 0.25 1.59 0.97 to 2.61 0.069
gender 0.09 0.25 1.09 0.66 to 1.79 0.737
Osa -0.27 0.55 0.76 0.26 to 2.23 0.620
Notes: Model coefficients: -2 log likelihood 606.568; χ2=38.938; P,0.001; n=166. The values in bold are considered statistically significant (P,0.05).
Abbreviations: arF, acute respiratory failure; hCO3
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, survival would be positively influenced. 
In the present study, we did not find this, even not in a 
separate analysis of those patients with severe hypercapnia 
before NIV initiation.
The present study did show that the level of arterial bicar-
bonate at initiation is a strong predictor for both the change 
in PaCO
2
 and prognosis, independent from confounders as 
diuretic use, which is known to affect arterial bicarbonate. 
This is interesting as in clinical practice, NIV is both initiated 
and monitored based on PaCO
2
. Budweiser et al demonstrated 
that arterial base excess, in addition to BMI and hyperinfla-
tion, was an independent predictor for prognosis in COPD 
patients treated with NIV.14 They suggested that daytime 
base excess might better represent nocturnal hypoventilation 
than daytime PaCO
2
 as the increased level of base excess is 
a renal compensatory mechanism for chronically elevated 
levels of PaCO
2
.14 As bicarbonate is the predominant base 
contributing to base excess, our study supports this finding. 
We suggest that this marker of CHRF might be a therapeutic 
target for NIV and that NIV should be initiated and monitored 
based on bicarbonate. In addition, this finding suggests that 
patients with high bicarbonate levels will potentially be better 
responders to NIV.
The present study also shows that a higher BMI is associ-
ated with a better survival, independent from confounders 
like the presence of OSA. This is not a new finding as a 
cohort study by Borel et al showed that NIV is associated 
with better prognosis only in a subgroup of obese patients 
(BMI .30 kg/m2),15 a finding supported by Budweiser et al 
and Yang et al.13,14 We hypothesize that in the obese patients, 
hypercapnia is probably not solemnly a marker of severe lung 
disease. Sleep hypoventilation due to obesity itself can con-
tribute to the hypercapnia in these patients. This mechanism 
is potentially less harmful to the patient and may explain the 
better prognosis of these obese patients.
Patients initiated on NIV after an episode of ARF had 
worse survival rates compared to the patients initiated in 
stable condition, despite the fact that patients initiated 
following an acute exacerbation did respond well in terms 
of improvements in hypercapnia. Analysis revealed that 
these patients had a larger reduction in PaCO
2
 compared 
to stable patients, independent of bicarbonate levels. 
The RCT of Struik et al, from which trial patient data 
were used for the current analysis, revealed that initiat-
ing chronic NIV directly after an episode of ARF is not 
beneficial and that mortality of these patients remains 
high,9 despite the fact that PaCO
2
 was reduced more when 
NIV was applied compared to the standard arm in which 
spontaneous recovery was awaited. However, a major 
determinant for future exacerbations and death are a his-
tory of exacerbations and hospitalizations due to exacerba-
tions of COPD, regardless of disease severity.16,17 As the 
patients initiated after an exacerbation indeed did suffer 
from more exacerbations compared to the patients initi-
ated in stable disease, also after the start of the therapy, 
it was not surprising that the current evaluation identified 
Figure 2 survival curves of patients initiated on nIV. (A) Patients initiated on nIV in stable condition and after a COPD exacerbation, corrected for the remaining predictors. 
(B) survival curves referring to the percentage of change in PaCO2 after 12 months for a subgroup of patient (n=69) with baseline PaCO2 .7.0 kPa.
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Improvement in hypercapnia does not predict survival in COPD patients
that patients initiated after an exacerbation had a worse 
prognosis compared to the stable patients. Nevertheless, it 
is encouraging that recent evidence has shown that chronic 
NIV might prevent exacerbations in a subgroup of frail 
severe persistent hypercapnic patients, an effect that might 
eventually also affect survival.18,19
Some findings of our study were surprising. First, patients 
with anxious or depressive feelings did not have a worse 
outcome. Physicians are often reluctant toward initiating 
these patients on NIV as in daily practice, they are known 
to have difficulties adapting to NIV and show poor compli-
ance. However, in this study, NIV was not terminated more 
often due to noncompliance in patients feeling anxious or 
depressed. Furthermore, compliance at 3 months did not 
differ between patients suffering of these symptoms, and 
those without anxious or depressed feelings. Although no 
data are available about the time and effort it took to adapt 
these patients to the ventilator, they eventually seem to 
adapt rather well. Notably, the present study revealed that 
patients with anxiety symptoms responded well to NIV as 
they demonstrated a larger reduction in PaCO
2
, independent 
from baseline bicarbonate levels (representing severity of 
hypercapnia). We speculate that anxious patients over time 
might adopt an unfavorable breathing pattern, with increased 
respiratory rates that can induce air trapping. If so, NIV has 
great potential in improving breathing patterns at night, per-
haps explaining why these patients seem to respond well to 
NIV. Therefore, we believe that there is no reason to doubt 
the indication of NIV in anxious COPD patients with CHRF. 
Moreover, they might be a subgroup that could benefit most 
from NIV.
This study confirms that higher inspiratory pressures 
are necessary for improvements in hypercapnia and hereby 
strengthens the evidence for high-intensity NIV. Surpris-
ingly, however, compliance was not associated with the 
change in PaCO
2
, a finding not in line with the general con-
sensus. However, compliance of the patients in the present 
study was excellent. Approximately 80% of the patients used 
NIV for more than 5 hours per night, which is the suggested 
minimum to achieve a substantial improvement in hypercap-
nia and survival.15,20 In the Netherlands, the HMV centers 
accommodate a unique system with comprehensive care and 
monitoring at the patients’ home, frequent home visits, and a 
24/7 service in case of problems. We acknowledge that this 
may enhance compliance. The general thought exists that 
adherence of COPD patients to the ventilator is poor. The 
present study indicates that this needs to be reconsidered, at 
least when sufficient care and monitoring is provided.
Finally, our study does have some limitations. First, we 
acknowledge the lack of a control group. In addition, missing 
data were a concern as we had to exclude potential significant 
parameters as hyperinflation and HRQL from the multivariate 
analysis.21–23 Also, the number of missing data might not be 
equal between patient initiated in stable condition compared 
to patients initiated following an exacerbation, as in the latter 
group more patients were RCT recruited. We also acknowl-
edge that OSA was not assessed by a polygraphy in all 
patients and therefore possibly leading to an underestimation 
of the presence of OSA. These limitations might have biased 
our results. Finally, causes of death could not be retrieved 
for all patients, so we could not differentiate between COPD 
and other causes of death.
Conclusion
Patients with anxiety symptoms and patients with high 
bicarbonate levels at initiation of NIV might be potential 
responders to NIV in terms of an improvement in hyper-
capnia. This improvement in hypercapnia, however, seems 
not to be associated with an improved survival. This finding 
emphasizes the need to look beyond PaCO
2
 when consider-
ing NIV initiation, as other mechanisms and targets might 
be important when applying chronic NIV.
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Improvement in hypercapnia does not predict survival in COPD patients
Supplementary materials
Table S1 Prognostic value of baseline variables for the percentage of change in PaCO2 after 12 months for the whole group of COPD 
patients according to the univariate regression model
∆PaCO2a
nb R2 B 95% CI of B P-value
age (years) 105 0.042 0.314 0.022 to 0.606 0.035
gender (F) 105 0.002 -1.057 -6.120 to 4.005 0.680
BMI 99 0.018 0.290 -0.146 to 0.726 0.191
smoker 105 0.002 -1.340 -7.086 to 4.406 0.645
nIV started after arF 105 0.055 -6.061 -10.976 to 1.146 0.016
PaO2 (kPa) 102 0.018 -1.127 -2.776 to 0.523 0.178
hCO3
- (mmol/l) 102 0.247 -1.426 -1.919 to -0.932 ,0.001
FeV1 (% predicted) 99 0.019 0.176 -0.082 to 0.434 0.179
FeV1/FVC (%) 99 0.004 -0.084 -0.347 to 0.179 0.526
rV/TlC (%) 44 0.025 -0.215 -0.631 to 0.202 0.305
Diuretics 105 0.005 1.820 -3.214 to 6.854 0.475
srI, total score 68 0.110 0.288 0.087 to 0.490 0.006
Comorbid disease
Obstructive sleep apnea 92 0.007 4.323 -6.622 to 15.268 0.435
anxiety 96 0.040 -5.449 -10.941 to 0.044 0.052
Depression 95 0.038 -5.118 -10.429 to 0.193 0.059
Diabetes mellitus 102 0.004 -2.083 -8.772 to 4.607 0.538
hypertension 97 0.007 2.288 -3.214 to 7.791 0.411
Coronary artery disease 105 0.015 3.787 -2.114 to 9.688 0.206
Congestive heart failure 99 0.029 -6.001 -12,993 to 0.890 0.091
nIV settingsc
IPaP (cmh2O) 103 0.035 -0.638 -1.297 to 0.021 0.058
ePaP (cmh2O) 103 0.003 -0.421 -1.849 to 1.006 0.560
BUrr (breaths per minute) 103 0.004 -0.292 -1.209 to 0.625 0.529
Compliance (hours)c 78 0.014 -0.701 -2.048 to 0.647 0.304
Notes: aPercentage of change in PaCO2 after 12 months, a negative value indicates a decrease in PaCO2; 
bnumber of patients included in the analysis; cnIV settings and 
compliance after 12 months. The values in bold are considered statistically significant (P,0.05).
Abbreviations: arF, acute respiratory failure; BUrr, backup respiratory rate; ePaP, expiratory positive airway pressure; hCO3
-, arterial bicarbonate; IPaP, inspiratory 
positive airway pressure; nIV, noninvasive ventilation; PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; rV, residual volume; srI, severe respiratory 
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Table S2 Prognostic value of baseline variables and nIV settings on survival according to univariate Cox regression analysis
na HR 95% CI P-value
age (years) 233 1.032 1.008 to 1.056 0.008
BMI (kg/m2) 222 0.938 0.905 to 0.973 0.001
Pack years 169 1.000 0.992 to 1.008 0.981
gender (female) 233 0.733 0.504 to 1.068 0.106
living alone 212 0.891 0.548 to 1.448 0.641
nIV started after arF 233 2.106 1.420 to 3.124 ,0.001
PaO2 (kPa) 222 0.920 0.794 to 1.067 0.270
PaCO2 (kPa) 228 1.331 1.151 to 1.538 ,0.001
∆PaCO2 (%)b 104 0.988 0.965 to 1.012 0.320
∆PaCO2 (kPa)c 104 1.157 0.910 to 1.472 0.234
hCO3
- (mmol/l) 221 1.115 1.067 to 1.165 ,0.001
FeV1 (% predicted) 217 0.968 0.947 to 0.990 0.005
FeV1/FVC (%) 215 0.993 0.970 to 1.016 0.526
rV/TlC (%) 110 1.036 0.988 to 1.076 0.066
Diuretics 233 1.011 0.695 to 1.471 0.955
srI, total score 129 0.983 0.966 to 1.000 0.054
Comorbid disease
Obstructive sleep apnea 192 0.423 0.185 to 0.968 0.042
anxiety 209 1.347 0.900 to 2.016 0.148
Depression 207 0.849 0.567 to 1.273 0.428
Diabetes mellitus 225 1.369 0.859 to 2.182 0.186
hypertension 221 0.864 0.574 to 1.301 0.484
Coronary artery disease 222 1.086 0.632 to 1.866 0.765
Congestive heart failure 223 1.206 0.714 to 2.037 0.483
nIV settingsd
IPaP (cmh2O) 201 1.005 0.951 to 1.062 0.866
ePaP (cmh2O) 201 0.935 0.812 to 1.076 0.347
BUrr (breaths per minute) 201 1.018 0.949 to 1.092 0.623
Compliance (hours)d 146 0.934 0.812 to 1.074 0.338
Notes: anumber of patients included in the analysis; bPercentage of change in PaCO2 between baseline and 12 months; 
cabsolute change in PaCO2 between baseline and 
12 months; dNIV settings and compliance after 3 months. The values in bold are considered statistically significant (P,0.05). 
Abbreviations: arF, acute respiratory failure; BUrr, backup respiratory rate; ePaP, expiratory positive airway pressure; hCO3
-, arterial bicarbonate; IPaP, inspiratory 
positive airway pressure; nIV, noninvasive ventilation; PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; rV, residual volume; srI, severe respiratory 
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